We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Seeks More Immunogenicity Testing For Low Molecular Weight Heparins
FDA Seeks More Immunogenicity Testing For Low Molecular Weight Heparins
The FDA wants manufacturers of low molecular weight heparin (LMWH) products to do a better job of assessing immunogenicity risk before submitting their products for approval.